Physician profile
Michael M Chen
NPI 1487711123
$10,531.79
in general payments reported to CMS, 2019-2025
51 companies · $1,053 in 2025
The $1,053 reported for 2025 was more than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,518 · 2020: $1,118 · 2021: $2,437 · 2022: $849 · 2023: $2,459 · 2024: $1,096 · 2025: $1,053.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,610 · Travel and Lodging: $1,663 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,610.42 |
| Travel and Lodging | $1,663.17 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $334.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,682.77 | 2022-2023 | Pipeline |
| Biohaven Pharmaceuticals, INC. | $1,301.99 | 2021 | |
| Abbvie INC. | $1,248.63 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Collegium Pharmaceutical, INC. | $1,177.54 | 2019-2025 | Xtampza, Belbuca, Nucynta |
| Pfizer INC. | $852.85 | 2019-2025 | |
| Boston Scientific Corporation | $493.56 | 2019-2025 | Wavewriter Alpha Prime 16, General - Therapies |
| Biodelivery Sciences International, INC. | $433.55 | 2019-2021 | |
| Radius Health, INC. | $360.56 | 2019-2025 | Tymlos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $320.48 | 2019-2025 | Relistor |
| Amgen INC. | $289.99 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $254.76 | 2019-2024 | Ztlido |
| Zyla Life Sciences, INC. | $240.48 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $219.28 | 2022-2024 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $175.48 | 2020-2022 | |
| Eisai INC. | $139.83 | 2021-2022 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.